BioDlink International (HKG:1875) recorded an attributable loss of 3.4 million yuan in the nine months ended Sept. 30, compared with an attributable profit of 35.4 million yuan a year prior, a Tuesday Hong Kong bourse filing said.
The biopharmaceutical company's revenue for the three quarters fell 23% to 621.7 million yuan from 809 million yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.